Dalton Medicinal Chemistry Partners Signs Agreement with Boehringer Ingelheim
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Dalton Medicinal Chemistry Partners, the Medicinal Chemistry arm of Dalton Pharma Services, announces the signing of a Medicinal Chemistry agreement with Boehringer Ingelheim (Canada) Ltd.
Dalton Medicinal Chemistry Partners will utilise their medicinal chemistry expertise to design and synthesise novel compounds against a number of antiviral targets selected by Boehringer Ingelheim (Canada) Ltd.
Peter Pekos, President of Dalton Pharma Services, said: "We are pleased to enter this exciting partnership with Boehringer Ingelheim (Canada) Ltd by bringing the added value of our medicinal chemistry capabilities and expertise to their antiviral research projects."
